Clinical Trial: Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in People With Treatment-Resistant Schizophrenia

U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07184619) titled 'Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in People With Treatment-Resistant Schizophrenia' on Sept. 18.

Brief Summary: This is a prospective, 12-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center study designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid (30 mg/day) in outpatients with treatment-resistant schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient's current antipsychotic medication(s). Approximately 400 patients will be randomized at a 1:1 ratio to receive either evenamide or pla...